OClawVPS.com
Calculus Capital
Edit

Calculus Capital

https://www.calculuscapital.com
Last activity: 04.04.2026
Active
Calculus Capital is a specialist in creating and managing private equity funds for individuals. Calculus Capital is a pioneer in the tax-efficient industry having set up the UK’s first approved EIS fund in 1999. Since then we have launched 21 EIS funds and 5 VCT share class issues.

The firms focus and investment has remained consistent: building diversified portfolios across a multitude of sectors, of smaller, UK, entrepreneurial growth companies and creating value for our investors through our multi award winning funds. We have provided significant results for our clients either via tax free dividends (for our VCT investors) or tax free capital gains (for our EIS investors).

In addition, we have launched a new fund in June 2019, the UK Creative Content EIS Fund in association with the British Film Institute.

Calculus Capital is authorised and regulated by the Financial Conduct Authority.
News
332
Portfolio
5
Mentions
35
Location: United Kingdom, England, London
Employees: 11-50
Founded date: 1999

Portfolio 5

DateNameWebsiteTotal RaisedLocation
06.10.2025Trogenixtrogenix.com$94.43MUnited Kin...
28.08.2025EnsiliTechensilitech.com$7.18MUnited Kin...
08.09.2022Optalitixoptalitix.com$7.62M-
07.02.2018Open Energ...openenergymarket.com$4.16MUnited Kin...
09.01.2017Jumptasticjumptastic.uk$3.73MUnited Kin...

News 332

DateTitleDescription
18.03.2026Resurrect Bio and Corteva Join Forces to Unlock Nature’s Own Defenses in Corn-
23.02.2026Wonderhood mastermind new Waitrose and Hargreaves Lansdown adverts-
18.02.2026Calculus invests in Resurrect Bio-
27.01.2026Beyond the Usual Suspects: Rethinking Business Relief for IHT Planning-
19.01.2026Oxford BioTherapeutics and C4X recognised in the 2026 edition of The Sunday Times 100 Tech-
16.12.2025Smartr365 Mortgage Technology Expansion-
10.12.2025Wonderhood Studios produce Waitrose Christmas advert-
10.12.2025Oxford BioTherapeutics Signs Strategic Collaboration with GSK to Discover Novel Antibody-Based Cancer Therapeutics-
26.11.2025Autumn Budget 2025 Response-
05.11.2025Calculus successfully exits employee engagement platform Mo (Thanksbox Limited)-
Show more

Mentions in press and media 35

DateTitleDescription
06.11.2025DIGIT Deal Roundup | October 2025Welcome to October 2025’s DIGIT Deal Roundup. Christmas came very early for a raft of Scottish firms last month, with tens of millions in fresh investment targeting Scotland’s medtech stars, robot builders, EV makers, and agri-tech innovato...
13.10.2025Trogenix: $95 Million Series A Closed For Advancing Clinical Development Of Curative Cancer TherapiesTrogenix, a biotech company dedicated to developing innovative therapies for cancer treatment, announced the closing of its Series A financing round at £70 million (approximately $95 million). This funding will accelerate the development of...
07.10.2025Precision Oncology Pioneer Trogenix Secures Landmark €80M Series A for Curative Cancer FightTrogenix, an Edinburgh-based biotech, secured a monumental €80 million Series A funding. This capital empowers its pursuit of curative cancer treatments for aggressive solid tumors. The firm's Odysseus platform uses advanced gene control an...
06.10.2025Edin Uni Spinout Trogenix Raises £70M to Treat Aggressive CancersUniversity of Edinburgh spinout Trogenix, which is developing curative therapies for aggressive, treatment-resistant cancers, has completed Series A financing of £70 million. The funding will allow the biotech company to rapidly advance its...
06.10.2025Edinburgh-based BioTech Trogenix lands €80 million to accelerate curative cancer treatmentsTrogenix Ltd, a Scottish BioTech company dedicated to innovative cancer therapies, announced the completion of its Series A financing, raising €80 million, to advance its pipeline of potentially curative cancer therapies across multiple agg...
29.08.2025EnsiliTech Secures €5.2M to Revolutionize Global Medicine TransportEnsiliTech, a Bristol-based biotech pioneer, just closed a significant €5.2 million seed funding round. This capital injection accelerates its patented Ensilication technology. This innovation eliminates the outdated, expensive cold chain. ...
28.08.2025Calculus invests in EnsiliTech as part of £4.5M raise-
28.08.2025EnsiliTech raises £4.5M to advance medicine formulationBristol-based biotechnology startup EnsiliTech has raised its second oversubscribed funding round, securing £4.5 million in seed funding to improve the way life-saving medicines are stored and transported globally. Today’s biopharmaceutical...
28.08.2025British BioTech startup EnsiliTech raises €5.2 million to cut cold-chain costs in biopharma transportEnsiliTech, a Bristol-based BioTech startup, has secured €5.2 million in Seed funding to revolutionise the way life-saving medicines are stored and transported globally. The round was led by Eos Advisory and joined by Calculus Capital, Empi...
24.09.2024Invizius Secures £950K to Revolutionize Dialysis TreatmentIn the heart of Edinburgh, a biotech company is on the brink of a breakthrough. Invizius has raised £950,000 in funding, a crucial step toward transforming dialysis treatment. This funding round, led by Mercia Ventures, is a beacon of hope ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In